# Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes

> **NCT01615978** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 15 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01615978
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01615978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01615978, "Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01615978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*